Literature DB >> 2447293

Two proteins with reverse transcriptase activities associated with hepatitis B virus-like particles.

M R Bavand1, O Laub.   

Abstract

Recent studies suggest that hepatitis B virus (HBV), despite being a DNA virus, replicates via an RNA intermediate (R. H. Miller, P. L. Marion, and S. W. Robinson, Virology 139:64-72, 1984; J. Summers and W. S. Mason, Cell 29:403-415, 1982). The HBV life cycle is therefore a permuted version of the RNA retroviral life cycle. Sequence homology between retroviral reverse transcriptase and the putative HBV polymerase gene product suggests the presence of an HBV reverse transcriptase (H. Toh, H. Hajashida, and T. Miyata, Nature (London) 305:827-829, 1983). As yet, there has been no direct evidence that reverse transcriptase activity is present in the viral particle. We used activity gel analysis to detect the in situ catalytic activities of DNA polymerases after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Our studies demonstrated that HBV-like particles secreted by a differentiated human hepatoma cell line transfected with genomic HBV DNA contain two major polymerase activities which migrate as approximately 90- and approximately 70-kilodalton (kDa) proteins. This demonstrated, for the first time, that HBV-like particles contain a novel DNA polymerase-reverse transcriptase activity. Furthermore, we propose that the 70-kDa reverse transcriptase may be produced by proteolytic self-cleavage of the 90-kDa precursor protein.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2447293      PMCID: PMC250580     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  15 in total

1.  Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA.

Authors:  C Sureau; J L Romet-Lemonne; J I Mullins; M Essex
Journal:  Cell       Date:  1986-10-10       Impact factor: 41.582

2.  Virus-like particles in serum of patients with Australia-antigen-associated hepatitis.

Authors:  D S Dane; C H Cameron; M Briggs
Journal:  Lancet       Date:  1970-04-04       Impact factor: 79.321

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 4.  Persistent infection of humans with hepatitis B virus: mechanisms and consequences.

Authors:  D Ganem
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

5.  Putative reverse transcriptase intermediates of human hepatitis B virus in primary liver carcinomas.

Authors:  H Will; J Salfeld; E Pfaff; C Manso; L Theilmann; H Schaler
Journal:  Science       Date:  1986-02-07       Impact factor: 47.728

6.  Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus.

Authors:  H Toh; H Hayashida; T Miyata
Journal:  Nature       Date:  1983 Oct 27-Nov 2       Impact factor: 49.962

7.  Synthesis of hepatitis B surface antigen in mammalian cells: expression of the entire gene and the coding region.

Authors:  O Laub; L B Rall; M Truett; Y Shaul; D N Standring; P Valenzuela; W J Rutter
Journal:  J Virol       Date:  1983-10       Impact factor: 5.103

8.  Hepatitis B viral DNA-RNA hybrid molecules in particles from infected liver are converted to viral DNA molecules during an endogenous DNA polymerase reaction.

Authors:  R H Miller; P L Marion; W S Robinson
Journal:  Virology       Date:  1984-11       Impact factor: 3.616

9.  RNA-dependent DNA polymerase activity in cauliflower mosaic virus-infected plant leaves.

Authors:  M Volovitch; N Modjtahedi; P Yot; G Brun
Journal:  EMBO J       Date:  1984-02       Impact factor: 11.598

10.  Hepatitis B surface antigen produced by a human hepatoma cell line.

Authors:  G M MacNab; J J Alexander; G Lecatsas; E M Bey; J M Urbanowicz
Journal:  Br J Cancer       Date:  1976-11       Impact factor: 7.640

View more
  19 in total

1.  Viral DNA carried by human immunodeficiency virus type 1 virions.

Authors:  F Lori; F di Marzo Veronese; A L de Vico; P Lusso; M S Reitz; R C Gallo
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

2.  cis rescue of a mutated reverse transcriptase gene of human hepatitis B virus by creation of an internal ATG.

Authors:  S Roychoudhury; C Shih
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

3.  Effects of insertional and point mutations on the functions of the duck hepatitis B virus polymerase.

Authors:  L J Chang; R C Hirsch; D Ganem; H E Varmus
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

4.  Evidence that less-than-full-length pol gene products are functional in hepadnavirus DNA synthesis.

Authors:  T T Wu; L D Condreay; L Coates; C Aldrich; W Mason
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

5.  Efficient pyrophosphorolysis by a hepatitis B virus polymerase may be a primer-unblocking mechanism.

Authors:  S Urban; S Urban; K P Fischer; D L Tyrrell
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

Review 6.  Viral hepatitis.

Authors:  J Y Lau; G J Alexander; A Alberti
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

7.  Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity.

Authors:  G Radziwill; W Tucker; H Schaller
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

8.  Internal entry of ribosomes and ribosomal scanning involved in hepatitis B virus P gene expression.

Authors:  O Jean-Jean; T Weimer; A M de Recondo; H Will; J M Rossignol
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

9.  Hepatitis B virus particles contain a polypeptide encoded by the largest open reading frame: a putative reverse transcriptase.

Authors:  D H Mack; W Bloch; N Nath; J J Sninsky
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

10.  The hepatitis B virus-associated reverse transcriptase is encoded by the viral pol gene.

Authors:  M Bavand; M Feitelson; O Laub
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.